Takeda officer plans $363K stock sale in 2026

TAKEDA PHARMACEUTICAL CO LTD (TAK) received a Rule 144 notice covering a planned sale of common stock beneficially owned for the account of officer Andrew Stewart Plump.

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD (TAK) received a Rule 144 notice covering a planned sale of common stock beneficially owned for the account of officer Andrew Stewart Plump. The filing indicates plans to sell 19,651 shares of TAK common stock through Fidelity Brokerage Services LLC on or about August 19, 2026 on the NYSE.

The shares to be sold were acquired from the issuer on August 20, 2020 as RSU's and PSU's and are held in the ANDREW S PLUMP 2020 REV TR U/A 12/2/20. The filing lists an aggregate market value of $363,348.49 for the proposed sale and shows 1,579,836,830 shares outstanding of TAK common stock as context.

Key Figures

Shares to be sold: 19,651 shares Aggregate market value: $363,348.49 Shares outstanding: 1,579,836,830 shares +3 more

6 metrics

Shares to be sold 19,651 shares Planned Rule 144 sale of Takeda common stock

Aggregate market value $363,348.49 Reported value of the 19,651 TAK shares to be sold

Shares outstanding 1,579,836,830 shares Takeda common shares outstanding listed in the Form 144

Planned sale date 08/19/2026 Approximate date of sale for the Rule 144 transaction

Acquisition date 08/20/2020 Date the RSU's and PSU's were acquired from the issuer

Trust reference date 12/2/20 Date in the name of the ANDREW S PLUMP 2020 REV TR U/A 12/2/20

Key Terms

Rule 144, RSU's and PSU's, attorney-in-fact, Form 144

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU's and PSU's financial

"Common | 08/20/2020 | RSU's and PSU's | Issuer"

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Form 144 regulatory

"144: Filer Information Filer CIK"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

What does the Form 144 filing disclose about TAK (Takeda Pharmaceutical Co Ltd)?

The filing discloses a planned Rule 144 sale of 19,651 TAK common shares beneficially owned for officer Andrew Stewart Plump. The shares are to be sold through Fidelity on or about August 19, 2026 on the NYSE.

How many TAK (Takeda) shares are planned to be sold under this Form 144?

The notice covers a proposed sale of 19,651 shares of TAK common stock. These shares were acquired as RSU's and PSU's on August 20, 2020 and are currently held in the ANDREW S PLUMP 2020 REV TR U/A 12/2/20.

What is the approximate market value of the TAK shares in this Form 144 filing?

The Form 144 lists an aggregate market value of $363,348.49 for the 19,651 TAK common shares subject to the planned sale. This value is reported in the securities information section of the filing.

When were the TAK shares being sold under this Form 144 originally acquired?

The shares were acquired from Takeda on August 20, 2020 as RSU's and PSU's. The filing identifies the issuer as the source of the securities and specifies the acquisition date in the securities-to-be-sold section.

How many TAK (Takeda) shares are shown as outstanding in this Form 144?

The Form 144 lists 1,579,836,830 shares outstanding of Takeda common stock. This figure appears in the securities information section as context for the 19,651 shares covered by the planned sale.

Who is the beneficial owner associated with the TAK Form 144 sale notice?

The notice is filed for the account of Andrew Stewart Plump, identified as an officer. The shares are noted as being sold from the ANDREW S PLUMP 2020 REV TR U/A 12/2/20, with Fidelity acting under a power of attorney.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 03:59 PM Accepted by SEC EDGAR 08/19/2026 - 03:58 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977689
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TAKEDA PHARMACEUTICAL CO LTD
SEC File Number	001-38757
Address of Issuer	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO JAPAN 103-8668
Phone	81332782111
Name of Person for Whose Account the Securities are To Be Sold	Plump Andrew Stewart
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	19651	363348.49	1579836830	08/19/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2020	RSU's and PSU's	Issuer			19651	08/20/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	shares are being sold from ANDREW S PLUMP 2020 REV TR U/A 12/2/20
Date of Notice	08/19/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Audrey Skillern as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Andrew Stewart Plump
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)